Abstract
Tuberculosis (TB) with central nervous system (CNS) manifestation is a form of TB with a high mortality and morbidity. Tuberculous meningitis (TM) is the most common form of CNS-TB. Although diagnosis of CNS-TB can be challenging, early treatment of CNS-TB is related to a better outcome. If CNS-TB is suspected, even though the clinical picture is not specific, it should be immediately treated.
For the treatment of CNS-TB, knowledge of the penetration across the blood-brain barrier of the various antituberculosis agents used in TB treatment is important. These will be described here in order to serve as a guide in choosing a treatment for CNS-TB. Corticosteroids have an evidence-based value in the treatment of TM and so are recommended. As for thalidomide use in CNS-TB, sound evidence is still lacking. We will also include a description of the adverse neurotoxic effects of the various other agents including their psychiatric, ototoxic and ophthalmic adverse effects.
Keywords: Tuberculosis, central nervous system, tuberculous meningitis, antituberculosis agents, blood-brain barrier, corticosteroids, thalidomide, adverse neurotoxic effects, HIV infection, enzyme-linked immunospot assay (ELISpot assay)
Current Pharmaceutical Design
Title: Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Volume: 17 Issue: 27
Author(s): J. J. van der Harst and G. J. Luijckx
Affiliation:
Keywords: Tuberculosis, central nervous system, tuberculous meningitis, antituberculosis agents, blood-brain barrier, corticosteroids, thalidomide, adverse neurotoxic effects, HIV infection, enzyme-linked immunospot assay (ELISpot assay)
Abstract: Tuberculosis (TB) with central nervous system (CNS) manifestation is a form of TB with a high mortality and morbidity. Tuberculous meningitis (TM) is the most common form of CNS-TB. Although diagnosis of CNS-TB can be challenging, early treatment of CNS-TB is related to a better outcome. If CNS-TB is suspected, even though the clinical picture is not specific, it should be immediately treated.
For the treatment of CNS-TB, knowledge of the penetration across the blood-brain barrier of the various antituberculosis agents used in TB treatment is important. These will be described here in order to serve as a guide in choosing a treatment for CNS-TB. Corticosteroids have an evidence-based value in the treatment of TM and so are recommended. As for thalidomide use in CNS-TB, sound evidence is still lacking. We will also include a description of the adverse neurotoxic effects of the various other agents including their psychiatric, ototoxic and ophthalmic adverse effects.
Export Options
About this article
Cite this article as:
J. van der Harst J. and J. Luijckx G., Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470237
DOI https://dx.doi.org/10.2174/138161211797470237 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibiotics in Endophthalmitis: Microbiological and Pharmacokinetic Considerations
Current Clinical Pharmacology Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Editorial
Current Medical Imaging Bacterial Protein Microarrays for Diagnosis of Infectious Diseases
Current Immunology Reviews (Discontinued) Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology Drainage of Cerebral Abscesses Prior to Valve Replacement in Stable Patients with Acute Left-Sided Infective Endocarditis
CNS & Neurological Disorders - Drug Targets Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme
Current Medicinal Chemistry CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Peroxisome Proliferator-Activated Receptor-γ and Its Ligands in the Treatment of Tumors in the Nervous System
Current Stem Cell Research & Therapy Strategies to Create a Regenerating Environment for the Injured Spinal Cord
Current Pharmaceutical Design Increasing Bcl-2 and Neuroglubin Expression in Hypoxic Hippocampal Neurons under Hypoxia Preconditioning and in 3-n-butylphalide Treated Cells under Oxygen Glucose Deprivation/Reoxygenation
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC
Current Pharmaceutical Design Cefepime and its Role in Pediatric Infections
Recent Patents on Anti-Infective Drug Discovery Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review
Current Cardiology Reviews Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Advances in Drug Discovery and Development for Pediatric Tuberculosis
Mini-Reviews in Medicinal Chemistry Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update
Current Molecular Medicine Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews An Update on the Synthesis and Antibacterial Effects of Carbapenems
Recent Patents on Anti-Infective Drug Discovery